6OS2

Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV026


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.7 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.233 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR.

Wingler, L.M.Skiba, M.A.McMahon, C.Staus, D.P.Kleinhenz, A.L.W.Suomivuori, C.M.Latorraca, N.R.Dror, R.O.Lefkowitz, R.J.Kruse, A.C.

(2020) Science 367: 888-892

  • DOI: 10.1126/science.aay9813
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Biased agonists of G protein-coupled receptors (GPCRs) preferentially activate a subset of downstream signaling pathways. In this work, we present crystal structures of angiotensin II type 1 receptor (AT1R) (2.7 to 2.9 angstroms) bound to three ligan ...

    Biased agonists of G protein-coupled receptors (GPCRs) preferentially activate a subset of downstream signaling pathways. In this work, we present crystal structures of angiotensin II type 1 receptor (AT1R) (2.7 to 2.9 angstroms) bound to three ligands with divergent bias profiles: the balanced endogenous agonist angiotensin II (AngII) and two strongly β-arrestin-biased analogs. Compared with other ligands, AngII promotes more-substantial rearrangements not only at the bottom of the ligand-binding pocket but also in a key polar network in the receptor core, which forms a sodium-binding site in most GPCRs. Divergences from the family consensus in this region, which appears to act as a biased signaling switch, may predispose the AT1R and certain other GPCRs (such as chemokine receptors) to adopt conformations that are capable of activating β-arrestin but not heterotrimeric G q protein signaling.


    Organizational Affiliation

    Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA.,Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.,Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.,Department of Computer Science, Stanford University, Stanford, CA 94305, USA.,Biophysics Program, Stanford University, Stanford, CA 94305, USA.,Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA. lefko001@receptor-biol.duke.edu andrew_kruse@hms.harvard.edu.,Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA 94305, USA.,Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA. lefko001@receptor-biol.duke.edu andrew_kruse@hms.harvard.edu.,School of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.,Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.,Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Type-1 angiotensin II receptor,Soluble cytochrome b562 BRIL fusion protein
A
425Escherichia coliHomo sapiens
This entity is chimeric
Mutation(s): 1 
Gene Names: cybC, AGTR1 (AGTR1A, AGTR1B, AT2R1, AT2R1B)
Find proteins for P0ABE7 (Escherichia coli)
Go to UniProtKB:  P0ABE7
Find proteins for P30556 (Homo sapiens)
Go to Gene View: AGTR1
Go to UniProtKB:  P30556
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Nanobody Nb.AT110i1_le
D
128N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
TRV026 peptide
B
8N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
OLC
Query on OLC

Download SDF File 
Download CCD File 
A
(2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate
1-Oleoyl-R-glycerol
C21 H40 O4
RZRNAYUHWVFMIP-GDCKJWNLSA-N
 Ligand Interaction
NAG
Query on NAG

Download SDF File 
Download CCD File 
A
N-ACETYL-D-GLUCOSAMINE
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
CLR
Query on CLR

Download SDF File 
Download CCD File 
A
CHOLESTEROL
C27 H46 O
HVYWMOMLDIMFJA-DPAQBDIFSA-N
 Ligand Interaction
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
NH2
Query on NH2
B
NON-POLYMERH2 N

--

SAR
Query on SAR
B
PEPTIDE LINKINGC3 H7 N O2GLY
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.7 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.233 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 59.960α = 90.00
b = 101.350β = 90.00
c = 225.900γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
PDB_EXTRACTdata extraction
PHENIXrefinement
XDSdata reduction
XSCALEdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI)United StatesR01HL16037
National Institutes of Health/Office of the DirectorUnited States5DP5OD021345
Other privateUnited States--
Howard Hughes Medical Institute (HHMI)United States--

Revision History 

  • Version 1.0: 2020-02-19
    Type: Initial release
  • Version 1.1: 2020-03-04
    Type: Database references